Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

• Sponsor: Pfizer (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02969018
• Collaborator: (none)
• Enrollment: 212
• Locations: 44
• Arms: 8
• Actual Duration (Months): 14.9
• Patients Per Site: 4.8
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.

Condition or Disease	Intervention/Treatment	Phase
Chronic Plaque Psoriasis	Drug: PF-06700841; Other: Placebo	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 212 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
• Actual Study Start Date: Dec 1, 2016
• Actual Primary Completion Date: Mar 1, 2018
• Actual Study Completion Date: Mar 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: PF-06700841 60 mg followed by 30 mg once daily 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily	Drug: PF-06700841
Experimental: PF-06700841 60 mg followed by 10 mg once daily 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily	Drug: PF-06700841
Experimental: PF-06700841 60mg once daily followed by 100mg once weekly 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly	Drug: PF-06700841
Experimental: PF-06700841 60mg once daily followed by placebo once daily 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily	Drug: PF-06700841
Experimental: PF-06700841 30mg once daily 4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily	Drug: PF-06700841
Experimental: PF-06700841 30mg once daily followed by 10mg once daily 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily	Drug: PF-06700841
Experimental: PF-06700841 30mg once daily followed by 100mg once weekly 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly	Drug: PF-06700841
Placebo Comparator: Placebo 12 weeks once daily placebo	Other: Placebo

Outcome Measures

Primary Outcome Measures

1. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 [Baseline (Day 1 pre-dose), Week 12]

   The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Secondary Outcome Measures

1. Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12 [Week 12]

   A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

2. Change From Baseline in PASI Scores at Week 4 by Induction Dose [Baseline (Day 1 pre-dose), Week 4]

   Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

3. Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16 [Weeks 1, 2, 4, 6, 8, 10, 14, 16]

   A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

4. Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 [Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16]

   A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

5. Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 [Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16]

   A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

6. Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16 [Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16]

   The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

7. Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 [Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16]

   The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

8. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [From first dose of study treatment (Day 1) up to Week 20]

   An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

9. Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs [From first dose of study treatment (Day 1) up to Week 20]

   The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).

10. Change From Baseline in Blood Lipid Level at Weeks 4 and 12 [Baseline (Day 1 pre-dose), Weeks 4 and 12]

    Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.

11. Number of Participants With Any Post-Baseline Laboratory Test Abnormalities [From first dose of study treatment (Day 1) up to Week 16]

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).

12. Number of Participants With Post-Baseline Vital Sign Abnormalities [From first dose of study treatment (Day 1) up to Week 16]

    Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) <50 mmHg; 3) sitting pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP >=30 mmHg.

13. Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities [From first dose of study treatment (Day 1) up to Week 16]

    ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): >=140 milliseconds (msec), >=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): >=300 msec, >=25% change when baseline is > 200 msec or >=50% change when baseline is less than or equal to (<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of >=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to <480 msec, 480 to <500 msec, >=500 msec; a change from baseline of 30 to <60 msec or >=60 msec.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug)

• Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline/Day 1 (prior to first dose of study drug)

• Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug)

• Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)

Exclusion Criteria:

• Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed

• Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis

• Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA)

• Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).

• Have taken Apremilast (Otezla) within 3 months of first dose of study drug.

• Have undergone treatment with tofacitinib within 3 months of first dose.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA	Rogers	Arkansas	United States	72758
2	Anaheim Clinical Trials, LLC	Anaheim	California	United States	92801
3	California Dermatology & Clinical Research Institute	Encinitas	California	United States	92024
4	Emil A. Tanghetti, MD dba Center for Dermatology and Laser Surgery	Sacramento	California	United States	95819
5	Southern California Dermatology	Santa Ana	California	United States	92701
6	Tower Saint John's Imaging	Santa Monica	California	United States	90403
7	Clinical Science Institute	Santa Monica	California	United States	90404
8	Park Avenue Dermatology Administrative Annex	Orange Park	Florida	United States	32073
9	Park Avenue Dermatology	Orange Park	Florida	United States	32073
10	Olympian Clinical Research	Tampa	Florida	United States	33609
11	Rose Radiology	Tampa	Florida	United States	33609
12	Forward Clinical Trials, Inc	Tampa	Florida	United States	33624
13	Dundee Dermatology	West Dundee	Illinois	United States	60118
14	Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana	United States	46256
15	Dawes Fretzin Dermatology Group, LLC	Indianapolis	Indiana	United States	46256
16	Psoriasis Treatment Center of Central New Jersey	East Windsor	New Jersey	United States	08520
17	The Rockefeller University	New York	New York	United States	10065
18	Skin Search of Rochester, Inc.	Rochester	New York	United States	14623
19	Investigational Drug Services, UNC Hospitals	Chapel Hill	North Carolina	United States	27514
20	UNC Dermatology and Skin Cancer Center	Chapel Hill	North Carolina	United States	27516
21	UNC Clinical and Translation Research Center	Chapel Hill	North Carolina	United States	27599
22	Lynn Health Science Institute	Oklahoma City	Oklahoma	United States	73112
23	Vital Prospects Clinical Research Institute, P.C	Tulsa	Oklahoma	United States	74136
24	Health Concepts	Rapid City	South Dakota	United States	57702
25	Center for Clinical Studies	Houston	Texas	United States	77004
26	Lee Medical Associates, PA	San Antonio	Texas	United States	78213
27	Progressive Clinical Research, PA	San Antonio	Texas	United States	78213
28	Texas Dermatology and Laser Specialists	San Antonio	Texas	United States	78218
29	Virginia Clinical Research, Inc.	Norfolk	Virginia	United States	23502
30	Premier Clinical Research	Spokane	Washington	United States	99202
31	Wiseman Dermatology Research Inc.	Winnipeg	Manitoba	Canada	R3M 3Z4
32	Lynderm Research Inc	Markham	Ontario	Canada	L3P 1X2
33	Research by ICLS	Oakville	Ontario	Canada	L6J 7W5
34	Skin Centre for Dermatology	Peterborough	Ontario	Canada	K9J 5K2
35	The Centre for Dermatology	Richmond Hill	Ontario	Canada	L4B 1A5
36	K.Papp Clinical Research Inc.	Waterloo	Ontario	Canada	N2J 1C4
37	Diex Research Sherbrooke Inc.	Sherbrooke	Quebec	Canada	J1L 0H8
38	Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)	Quebec		Canada	G1V4X7
39	Centrum Medyczne Enel-Med Przychodnia Grunwaldzka	Gdansk		Poland	80-266
40	Centrum Badan Klinicznych PI-House Sp. z o.o.	Gdansk		Poland	80-546
41	Dermoklinika Centrum Medyczne s.c. M.Kierstan, J. Narbutt, A. Lesiak	Lodz		Poland	90-436
42	NZOZ "Nasz Lekarz" - Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna	Torun		Poland	87-100
43	MTZ Clinical Research Sp. z o.o.	Warszawa		Poland	02-106
44	WroMedica s.c.	Wroclaw		Poland	51-685

Sponsors and Collaborators

• Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center, Pfizer

Study Documents (Full-Text)

• Study Protocol - Feb 13, 2017
• Statistical Analysis Plan - Apr 10, 2018

More Information

Additional Information:

• To obtain contact information for a study center near you, click here.

Publications

None provided.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT02969018
• Other Study ID Numbers: B7931004; 2016-004049-96
• First Posted: Nov 21, 2016
• Last Update Posted: Mar 29, 2019
• Last Verified: Mar 1, 2019

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Keywords provided by Pfizer: plaque psoriasis
• Additional relevant MeSH terms: Psoriasis; PF-06700841

Study Results

Participant Flow

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Period Title: Overall Study
STARTED	25	29	26	25	29	25	30	23
COMPLETED	21	21	20	20	27	17	22	16
NOT COMPLETED	4	8	6	5	2	8	8	7

Baseline Characteristics

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo	Total
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.	Total of all reporting groups
Overall Participants	25	29	26	25	29	25	30	23	212
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	49.0 (14.69)	44.6 (13.71)	45.5 (12.93)	48.4 (15.47)	44.2 (10.92)	44.0 (11.56)	43.2 (12.28)	50.3 (12.23)	46.0 (13.04)
Age, Customized (Count of Participants)
18-44 Years	8 32%	14 48.3%	10 38.5%	8 32%	14 48.3%	12 48%	14 46.7%	8 34.8%	88 41.5%
45-64 Years	14 56%	13 44.8%	14 53.8%	13 52%	14 48.3%	13 52%	16 53.3%	12 52.2%	109 51.4%
>=65 Years	3 12%	2 6.9%	2 7.7%	4 16%	1 3.4%	0 0%	0 0%	3 13%	15 7.1%
Sex: Female, Male (Count of Participants)
Female	9 36%	8 27.6%	14 53.8%	4 16%	10 34.5%	8 32%	7 23.3%	4 17.4%	64 30.2%
Male	16 64%	21 72.4%	12 46.2%	21 84%	19 65.5%	17 68%	23 76.7%	19 82.6%	148 69.8%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	4 16%	4 13.8%	4 15.4%	2 8%	6 20.7%	5 20%	4 13.3%	4 17.4%	33 15.6%
Not Hispanic or Latino	21 84%	25 86.2%	22 84.6%	23 92%	23 79.3%	20 80%	26 86.7%	19 82.6%	179 84.4%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Race/Ethnicity, Customized (Count of Participants)
White	22 88%	27 93.1%	23 88.5%	24 96%	27 93.1%	22 88%	25 83.3%	19 82.6%	189 89.2%
Black or African American	3 12%	0 0%	3 11.5%	0 0%	1 3.4%	1 4%	1 3.3%	2 8.7%	11 5.2%
Asian	0 0%	1 3.4%	0 0%	1 4%	0 0%	0 0%	2 6.7%	0 0%	4 1.9%
American Indian or Alaska Native	0 0%	1 3.4%	0 0%	0 0%	0 0%	1 4%	0 0%	1 4.3%	3 1.4%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%	1 4%	1 3.3%	0 0%	2 0.9%
Other	0 0%	0 0%	0 0%	0 0%	1 3.4%	0 0%	1 3.3%	1 4.3%	3 1.4%

Outcome Measures

1. Primary Outcome

Title	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
Description	The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Baseline (Day 1 pre-dose), Week 12

Outcome Measure Data

Analysis Population Description

All randomized participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for Week 12.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	22	21	21	21	27	19	25	17
Least Squares Mean (90% Confidence Interval) [units on a scale]	-15.85	-10.56	-14.28	-10.14	-17.28	-13.27	-11.88	-7.21

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0005
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-8.64
	Confidence Interval	(2-Sided) 90%; -12.33 to -4.95
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.232
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by 10 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0963
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-3.34
	Confidence Interval	(2-Sided) 90%; -6.99 to 0.30
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.206
	Estimation Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW), Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0046
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-7.07
	Confidence Interval	(2-Sided) 90%; -10.76 to -3.37
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.233
	Estimation Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by Placebo, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0963
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-2.93
	Confidence Interval	(2-Sided) 90%; -6.63 to 0.77
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.238
	Estimation Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-10.07
	Confidence Interval	(2-Sided) 90%; -13.63 to -6.51
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.152
	Estimation Comments

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD Followed by 10 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0158
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-6.06
	Confidence Interval	(2-Sided) 90%; -9.79 to -2.33
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.255
	Estimation Comments

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD Followed by 100 mg QW, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	0.0488
	Comments	Hochberg adjusted p-value
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-4.66
	Confidence Interval	(2-Sided) 90%; -8.24 to -1.09
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 2.163
	Estimation Comments

2. Secondary Outcome

Title	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
Description	A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data at Week 12 after non-responder imputation applied.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Number (90% Confidence Interval) [percentage of participants]	60.0 240%	24.1 83.1%	57.7 221.9%	24.0 96%	86.2 297.2%	24.0 96%	36.7 122.3%	13.0 56.5%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	10.00
	Confidence Interval	(2-Sided) 90%; 2.95 to 33.87
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by 10 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.12
	Confidence Interval	(2-Sided) 90%; 0.61 to 7.36
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW), Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	9.09
	Confidence Interval	(2-Sided) 90%; 2.71 to 30.48
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by Placebo, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.11
	Confidence Interval	(2-Sided) 90%; 0.59 to 7.55
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	41.67
	Confidence Interval	(2-Sided) 90%; 10.80 to 160.68
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD Followed by 10 mg QD, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	2.11
	Confidence Interval	(2-Sided) 90%; 0.59 to 7.55
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 30 mg QD Followed by 100 mg QW, Placebo
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Odds Ratio (OR)
	Estimated Value	3.86
	Confidence Interval	(2-Sided) 90%; 1.17 to 12.74
	Parameter Dispersion	Type: Value:
	Estimation Comments
Other Statistical Analysis		Logistic regression

3. Secondary Outcome

Title	Change From Baseline in PASI Scores at Week 4 by Induction Dose
Description	Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Baseline (Day 1 pre-dose), Week 4

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data at Week 4.

Arm/Group Title	PF-06700841 60 mg QD as the Induction Dose	PF-06700841 30 mg QD as the Induction Dose	Placebo as the Induction Dose
Arm/Group Description	Participants received PF-06700841 60 mg QD as the induction dose.	Participants received PF-06700841 30 mg QD as the induction dose.	Participants received matching placebo QD as the induction dose.
Measure Participants	100	81	21
Least Squares Mean (90% Confidence Interval) [units on a scale]	-13.17	-12.16	-4.17

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD, PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-9.00
	Confidence Interval	(2-Sided) 90%; -11.43 to -6.57
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.470
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	PF-06700841 60 mg QD Followed by 10 mg QD, PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)
	Comments
	Type of Statistical Test	Other
	Comments
Statistical Test of Hypothesis	p-Value	<0.0001
	Comments
	Method	Mixed Models Analysis
	Comments
Method of Estimation	Estimation Parameter	Least Squares Mean Difference
	Estimated Value	-7.99
	Confidence Interval	(2-Sided) 90%; -10.48 to -5.51
	Parameter Dispersion	Type: Standard Error of the Mean; Value: 1.502
	Estimation Comments

4. Secondary Outcome

Title	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16
Description	A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Weeks 1, 2, 4, 6, 8, 10, 14, 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Week 1	0 0%	6.9 23.8%	7.7 29.6%	4.0 16%	0 0%	4.0 16%	0 0%	0 0%
Week 2	8.0 32%	13.8 47.6%	26.9 103.5%	12.0 48%	3.4 11.7%	8.0 32%	0 0%	0 0%
Week 4	24.0 96%	41.4 142.8%	61.5 236.5%	36.0 144%	27.6 95.2%	24.0 96%	36.7 122.3%	0 0%
Week 6	44.0 176%	41.4 142.8%	65.4 251.5%	36.0 144%	51.7 178.3%	28.0 112%	26.7 89%	8.7 37.8%
Week 8	60.0 240%	37.9 130.7%	65.4 251.5%	32.0 128%	65.5 225.9%	20.0 80%	40.0 133.3%	8.7 37.8%
Week 10	48.0 192%	24.1 83.1%	61.5 236.5%	32.0 128%	72.4 249.7%	28.0 112%	46.7 155.7%	13.0 56.5%
Week 14	48.0 192%	17.2 59.3%	34.6 133.1%	16.0 64%	75.9 261.7%	16.0 64%	16.7 55.7%	8.7 37.8%
Week 16	36.0 144%	10.3 35.5%	30.8 118.5%	20.0 80%	58.6 202.1%	12.0 48%	16.7 55.7%	8.7 37.8%

5. Secondary Outcome

Title	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Description	A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Week 1	12.0 48%	13.8 47.6%	19.2 73.8%	20.0 80%	10.3 35.5%	8.0 32%	3.3 11%	0 0%
Week 2	44.0 176%	37.9 130.7%	46.2 177.7%	32.0 128%	41.4 142.8%	20.0 80%	33.3 111%	0 0%
Week 4	60.0 240%	69.0 237.9%	69.2 266.2%	68.0 272%	69.0 237.9%	60.0 240%	66.7 222.3%	13.0 56.5%
Week 6	72.0 288%	62.1 214.1%	73.1 281.2%	68.0 272%	82.8 285.5%	60.0 240%	63.3 211%	26.1 113.5%
Week 8	72.0 288%	55.2 190.3%	73.1 281.2%	52.0 208%	86.2 297.2%	56.0 224%	63.3 211%	17.4 75.7%
Week 10	68.0 272%	44.8 154.5%	73.1 281.2%	48.0 192%	86.2 297.2%	48.0 192%	56.7 189%	17.4 75.7%
Week 12	68.0 272%	44.8 154.5%	69.2 266.2%	52.0 208%	89.7 309.3%	48.0 192%	53.3 177.7%	21.7 94.3%
Week 14	64.0 256%	44.8 154.5%	61.5 236.5%	48.0 192%	89.7 309.3%	36.0 144%	36.7 122.3%	26.1 113.5%
Week 16	60.0 240%	34.5 119%	53.8 206.9%	40.0 160%	79.3 273.4%	40.0 160%	36.7 122.3%	21.7 94.3%

6. Secondary Outcome

Title	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Description	A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Week 1	0 0%	3.4 11.7%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Week 2	0 0%	3.4 11.7%	7.7 29.6%	0 0%	0 0%	0 0%	0 0%	0 0%
Week 4	12.0 48%	20.7 71.4%	42.3 162.7%	16.0 64%	6.9 23.8%	8.0 32%	3.3 11%	0 0%
Week 6	16.0 64%	20.7 71.4%	26.9 103.5%	12.0 48%	24.1 83.1%	8.0 32%	20.0 66.7%	0 0%
Week 8	24.0 96%	17.2 59.3%	30.8 118.5%	8.0 32%	34.5 119%	4.0 16%	16.7 55.7%	0 0%
Week 10	28.0 112%	17.2 59.3%	26.9 103.5%	8.0 32%	34.5 119%	8.0 32%	13.3 44.3%	4.3 18.7%
Week 12	36.0 144%	13.8 47.6%	26.9 103.5%	8.0 32%	51.7 178.3%	8.0 32%	10.0 33.3%	4.3 18.7%
Week 14	28.0 112%	13.8 47.6%	11.5 44.2%	8.0 32%	37.9 130.7%	4.0 16%	13.3 44.3%	4.3 18.7%
Week 16	20.0 80%	3.4 11.7%	15.4 59.2%	4.0 16%	27.6 95.2%	8.0 32%	10.0 33.3%	4.3 18.7%

7. Secondary Outcome

Title	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16
Description	The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16

Outcome Measure Data

Analysis Population Description

"Number of participants analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). "Number analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Week 1	-5.74	-4.60	-5.85	-5.37	-3.97	-4.41	-3.46	-1.35
Week 2	-9.44	-8.35	-10.79	-9.49	-7.86	-7.79	-7.93	-2.28
Week 4	-12.85	-12.19	-14.11	-13.91	-11.72	-12.88	-13.06	-4.02
Week 6	-15.00	-12.12	-15.00	-13.85	-14.30	-14.33	-14.17	-5.52
Week 8	-15.94	-11.09	-14.97	-12.87	-15.82	-14.27	-13.83	-6.56
Week 10	-16.54	-9.89	-15.52	-11.64	-16.65	-14.98	-12.97	-6.78
Week 14	-15.47	-8.11	-13.31	-9.45	-16.14	-10.44	-11.03	-6.98
Week 16	-14.16	-6.59	-13.00	-7.83	-14.38	-9.62	-9.13	-6.76

8. Secondary Outcome

Title	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
Description	The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Time Frame	Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Outcome Measure Data

Analysis Population Description

"Number of participants analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). "Number analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Week 1	-26.70	-24.66	-30.25	-23.33	-20.92	-17.50	-15.42	-6.90
Week 2	-43.66	-44.17	-54.27	-42.58	-40.89	-32.46	-35.89	-12.81
Week 4	-57.16	-63.02	-72.41	-64.71	-60.76	-53.93	-58.99	-25.17
Week 6	-66.07	-63.31	-75.96	-65.06	-73.91	-58.57	-63.17	-33.49
Week 8	-70.11	-62.25	-77.05	-59.88	-81.04	-58.32	-61.38	-37.76
Week 10	-70.72	-57.55	-78.46	-53.81	-84.82	-61.23	-57.24	-39.68
Week 12	-71.94	-58.52	-74.42	-51.49	-88.68	-57.81	-58.57	-40.27
Week 14	-64.15	-47.87	-63.20	-44.30	-83.39	-47.84	-47.52	-39.48
Week 16	-57.28	-38.48	-60.56	-36.63	-74.18	-44.58	-42.29	-38.79

9. Secondary Outcome

Title	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Description	An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
Time Frame	From first dose of study treatment (Day 1) up to Week 20

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Treatment-emergent AEs	19 76%	21 72.4%	18 69.2%	18 72%	21 72.4%	16 64%	23 76.7%	13 56.5%
Treatment-emergent SAEs	2 8%	1 3.4%	1 3.8%	1 4%	0 0%	0 0%	0 0%	0 0%

10. Secondary Outcome

Title	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs
Description	The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).
Time Frame	From first dose of study treatment (Day 1) up to Week 20

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
Count of Participants [Participants]	2 8%	4 13.8%	1 3.8%	2 8%	0 0%	2 8%	2 6.7%	0 0%

11. Secondary Outcome

Title	Change From Baseline in Blood Lipid Level at Weeks 4 and 12
Description	Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.
Time Frame	Baseline (Day 1 pre-dose), Weeks 4 and 12

Outcome Measure Data

Analysis Population Description

"Number of participants analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). "Number analyzed" represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had data for each specified category.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	26	25	29	25	30	23
LDL Cholesterol, Week 4	15.91	11.27	15.00	15.88	8.96	-2.21	7.60	-6.28
LDL Cholesterol, Week 12	8.71	6.00	-0.74	6.85	14.10	-5.33	3.95	-4.00
HDL Cholesterol, Week 4	12.09	9.14	10.92	8.58	6.36	6.76	9.39	0.00
HDL Cholesterol, Week 12	5.00	5.48	2.48	-0.24	4.74	4.37	2.88	-2.73
Total Cholesterol, Week 4	34.39	29.46	31.32	26.33	15.14	10.36	14.00	-4.42
Total Cholesterol, Week 12	19.50	15.67	-1.86	7.05	20.37	0.68	4.33	-6.40
Triglycerides, Week 4	34.74	29.68	8.04	8.92	-65.11	19.60	-59.75	15.26
Triglycerides, Week 12	27.86	48.33	-85.00	2.67	-18.96	6.32	-67.79	1.87

12. Secondary Outcome

Title	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities
Description	Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).
Time Frame	From first dose of study treatment (Day 1) up to Week 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline laboratory data.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	25	25	28	25	30	23
Count of Participants [Participants]	17 68%	20 69%	20 76.9%	16 64%	21 72.4%	20 80%	18 60%	11 47.8%

13. Secondary Outcome

Title	Number of Participants With Post-Baseline Vital Sign Abnormalities
Description	Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) <50 mmHg; 3) sitting pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP >=30 mmHg.
Time Frame	From first dose of study treatment (Day 1) up to Week 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline vital signs data.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	25	29	25	25	28	25	30	23
Sitting DBP <50 mm Hg	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sitting DBP increase >=20 mm Hg	1 4%	1 3.4%	3 11.5%	2 8%	0 0%	0 0%	0 0%	0 0%
Sitting DBP decrease >=20 mm Hg	3 12%	0 0%	2 7.7%	2 8%	1 3.4%	2 8%	2 6.7%	1 4.3%
Sitting SBP <90 mm Hg	1 4%	1 3.4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sitting SBP increase >=30 mm Hg	1 4%	3 10.3%	2 7.7%	1 4%	0 0%	1 4%	0 0%	0 0%
Sitting SBP decrease >=30 mm Hg	2 8%	2 6.9%	1 3.8%	2 8%	1 3.4%	3 12%	2 6.7%	1 4.3%
Sitting pulse rate <40 bpm	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Sitting pulse rate >120 bpm	0 0%	0 0%	0 0%	0 0%	0 0%	1 4%	0 0%	0 0%

14. Secondary Outcome

Title	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
Description	ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): >=140 milliseconds (msec), >=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): >=300 msec, >=25% change when baseline is > 200 msec or >=50% change when baseline is less than or equal to (<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of >=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to <480 msec, 480 to <500 msec, >=500 msec; a change from baseline of 30 to <60 msec or >=60 msec.
Time Frame	From first dose of study treatment (Day 1) up to Week 16

Outcome Measure Data

Analysis Population Description

All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline ECG data.

Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	Participants received 12 weeks of blinded matching placebo QD tablets.
Measure Participants	24	29	25	25	28	25	28	22
PR interval >=300 msec	0 0%	0 0%	1 3.8%	0 0%	1 3.4%	0 0%	0 0%	0 0%
%Change in PR interval >=25/50%	0 0%	0 0%	0 0%	0 0%	0 0%	1 4%	0 0%	0 0%
QRS duration >=140 msec	0 0%	1 3.4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
%Change in QRS duration >=50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 3.3%	0 0%
QT interval >=500 msec	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
QTc >=450 to <480 msec	6 24%	1 3.4%	2 7.7%	0 0%	1 3.4%	1 4%	0 0%	1 4.3%
QTc >=480 to <500 msec	0 0%	0 0%	1 3.8%	0 0%	0 0%	0 0%	0 0%	1 4.3%
QTc >=500 msec	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
QTc change >=30 to <60 msec	2 8%	0 0%	2 7.7%	1 4%	3 10.3%	3 12%	0 0%	1 4.3%
QTc change >=60 msec	0 0%	0 0%	2 7.7%	0 0%	0 0%	0 0%	0 0%	1 4.3%

Adverse Events

Time Frame	From first dose of study treatment up to 20 weeks
Adverse Event Reporting Description	The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study.
Arm/Group Title	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD		PF-06700841 60 mg QD Followed by 10 mg QD		PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)		PF-06700841 60 mg QD Followed by Placebo		PF-06700841 30 mg QD		PF-06700841 30 mg QD Followed by 10 mg QD		PF-06700841 30 mg QD Followed by 100 mg QW		Placebo
Arm/Group Description	Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).		Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).		Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).		Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).		Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.		Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).		Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).		Participants received 12 weeks of blinded matching placebo QD tablets.
All Cause Mortality
	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD		PF-06700841 60 mg QD Followed by 10 mg QD		PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)		PF-06700841 60 mg QD Followed by Placebo		PF-06700841 30 mg QD		PF-06700841 30 mg QD Followed by 10 mg QD		PF-06700841 30 mg QD Followed by 100 mg QW		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/25 (4%)		0/29 (0%)		0/26 (0%)		0/25 (0%)		0/29 (0%)		0/25 (0%)		0/30 (0%)		0/23 (0%)
Serious Adverse Events
	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD		PF-06700841 60 mg QD Followed by 10 mg QD		PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)		PF-06700841 60 mg QD Followed by Placebo		PF-06700841 30 mg QD		PF-06700841 30 mg QD Followed by 10 mg QD		PF-06700841 30 mg QD Followed by 100 mg QW		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/25 (8%)		1/29 (3.4%)		1/26 (3.8%)		1/25 (4%)		0/29 (0%)		0/25 (0%)		0/30 (0%)		0/23 (0%)
Blood and lymphatic system disorders
Anaemia	0/25 (0%)	0	1/29 (3.4%)	1	0/26 (0%)	0	0/25 (0%)	0	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Cardiac disorders
Angina pectoris	1/25 (4%)	1	0/29 (0%)	0	0/26 (0%)	0	0/25 (0%)	0	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
General disorders
Chest pain	0/25 (0%)	0	0/29 (0%)	0	0/26 (0%)	0	1/25 (4%)	1	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Infections and infestations
Pneumonia	0/25 (0%)	0	0/29 (0%)	0	1/26 (3.8%)	1	0/25 (0%)	0	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Sepsis	0/25 (0%)	0	0/29 (0%)	0	1/26 (3.8%)	1	0/25 (0%)	0	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Injury, poisoning and procedural complications
Gun shot wound	1/25 (4%)	1	0/29 (0%)	0	0/26 (0%)	0	0/25 (0%)	0	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Other (Not Including Serious) Adverse Events
	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD		PF-06700841 60 mg QD Followed by 10 mg QD		PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)		PF-06700841 60 mg QD Followed by Placebo		PF-06700841 30 mg QD		PF-06700841 30 mg QD Followed by 10 mg QD		PF-06700841 30 mg QD Followed by 100 mg QW		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/25 (44%)		14/29 (48.3%)		13/26 (50%)		13/25 (52%)		13/29 (44.8%)		12/25 (48%)		16/30 (53.3%)		9/23 (39.1%)
Gastrointestinal disorders
Diarrhoea	0/25 (0%)	0	1/29 (3.4%)	1	0/26 (0%)	0	1/25 (4%)	1	0/29 (0%)	0	1/25 (4%)	1	3/30 (10%)	4	1/23 (4.3%)	1
Nausea	1/25 (4%)	1	1/29 (3.4%)	1	1/26 (3.8%)	1	2/25 (8%)	2	0/29 (0%)	0	0/25 (0%)	0	1/30 (3.3%)	1	2/23 (8.7%)	2
Cheilitis	0/25 (0%)	0	0/29 (0%)	0	0/26 (0%)	0	0/25 (0%)	0	2/29 (6.9%)	2	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Vomiting	0/25 (0%)	0	1/29 (3.4%)	1	1/26 (3.8%)	1	1/25 (4%)	1	0/29 (0%)	0	2/25 (8%)	2	0/30 (0%)	0	0/23 (0%)	0
General disorders
Fatigue	1/25 (4%)	1	1/29 (3.4%)	1	1/26 (3.8%)	1	2/25 (8%)	2	0/29 (0%)	0	1/25 (4%)	1	0/30 (0%)	0	1/23 (4.3%)	1
Infections and infestations
Upper respiratory tract infection	2/25 (8%)	2	1/29 (3.4%)	1	5/26 (19.2%)	5	1/25 (4%)	1	2/29 (6.9%)	2	0/25 (0%)	0	3/30 (10%)	3	1/23 (4.3%)	1
Bronchitis	0/25 (0%)	0	2/29 (6.9%)	2	0/26 (0%)	0	0/25 (0%)	0	2/29 (6.9%)	2	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Nasopharyngitis	4/25 (16%)	4	3/29 (10.3%)	4	3/26 (11.5%)	3	3/25 (12%)	3	5/29 (17.2%)	6	6/25 (24%)	6	4/30 (13.3%)	5	3/23 (13%)	3
Sinusitis	1/25 (4%)	1	0/29 (0%)	0	1/26 (3.8%)	2	2/25 (8%)	2	0/29 (0%)	0	0/25 (0%)	0	1/30 (3.3%)	1	0/23 (0%)	0
Urinary tract infection	0/25 (0%)	0	1/29 (3.4%)	1	1/26 (3.8%)	1	0/25 (0%)	0	0/29 (0%)	0	1/25 (4%)	1	2/30 (6.7%)	2	0/23 (0%)	0
Injury, poisoning and procedural complications
Ligament sprain	0/25 (0%)	0	1/29 (3.4%)	1	0/26 (0%)	0	0/25 (0%)	0	0/29 (0%)	0	2/25 (8%)	2	0/30 (0%)	0	0/23 (0%)	0
Investigations
Neutrophil count decreased	0/25 (0%)	0	0/29 (0%)	0	1/26 (3.8%)	1	0/25 (0%)	0	2/29 (6.9%)	2	0/25 (0%)	0	1/30 (3.3%)	1	0/23 (0%)	0
Musculoskeletal and connective tissue disorders
Back pain	1/25 (4%)	1	2/29 (6.9%)	2	0/26 (0%)	0	0/25 (0%)	0	2/29 (6.9%)	2	2/25 (8%)	2	1/30 (3.3%)	2	2/23 (8.7%)	2
Arthralgia	1/25 (4%)	3	2/29 (6.9%)	2	0/26 (0%)	0	0/25 (0%)	0	1/29 (3.4%)	1	1/25 (4%)	1	1/30 (3.3%)	1	1/23 (4.3%)	1
Nervous system disorders
Headache	1/25 (4%)	1	2/29 (6.9%)	2	3/26 (11.5%)	3	3/25 (12%)	3	4/29 (13.8%)	6	1/25 (4%)	1	0/30 (0%)	0	1/23 (4.3%)	1
Psychiatric disorders
Irritability	0/25 (0%)	0	0/29 (0%)	0	0/26 (0%)	0	2/25 (8%)	2	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain	0/25 (0%)	0	0/29 (0%)	0	1/26 (3.8%)	1	0/25 (0%)	0	2/29 (6.9%)	2	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0
Skin and subcutaneous tissue disorders
Psoriasis	0/25 (0%)	0	1/29 (3.4%)	1	3/26 (11.5%)	3	1/25 (4%)	1	0/29 (0%)	0	2/25 (8%)	2	0/30 (0%)	0	0/23 (0%)	0
Pruritus	0/25 (0%)	0	0/29 (0%)	0	1/26 (3.8%)	1	3/25 (12%)	4	1/29 (3.4%)	1	0/25 (0%)	0	1/30 (3.3%)	2	0/23 (0%)	0
Acne	0/25 (0%)	0	2/29 (6.9%)	2	0/26 (0%)	0	2/25 (8%)	2	0/29 (0%)	0	0/25 (0%)	0	2/30 (6.7%)	2	0/23 (0%)	0
Vascular disorders
Hot flush	0/25 (0%)	0	0/29 (0%)	0	0/26 (0%)	0	2/25 (8%)	2	0/29 (0%)	0	0/25 (0%)	0	0/30 (0%)	0	0/23 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.